Compare Norfolk Southern Corporation (NSC) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Natera Inc. Common Stock — how do they compare? Norfolk Southern Corporation trades at $325.86 (market cap $72.71B), while Natera Inc. Common Stock trades at $395.34 (market cap $57.03B). The key difference: Norfolk Southern Corporation is the larger of the two by market cap, and Norfolk Southern Corporation pays a 1.67% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 34 Days and Natera Inc. Common Stock for 0 Days on average.
| NSC | NTRA | |
|---|---|---|
Market Cap | $72.71B | $57.03B |
Volume | 652,004 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $352.98 | $425.64 |
52-Week Low | $278.19 | $179.42 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $88.26B | $56.18B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $325.42, up 1.33% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, a 21.02% net margin, and positive analyst sentiment. Recent developments include the pending Union Pacific merger and upcoming Q3 2026 earnings on October 22, 2026.
The stock presents growth potential with a $361.86 consensus price target and institutional accumulation, though risks include merger regulatory hurdles and fuel cost pressures. Current valuation at 27.62 P/E requires sustained earnings growth to justify further upside.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
